Chelsea Therapeutics International
Company: Chelsea Therapeutics International, Ltd.
Status: Acquired by Lundbeck (2014)
Headquarters: Charlotte, North Carolina, USA (previously)
Founded: 2004
Acquired by: H. Lundbeck A/S (June 2014, ~$658M deal)
Overview
flowchart TD
therapeutics["therapeutics"] -->|"protects against"| age_related_cognitive_decline["age-related cognitive decline"]
therapeutics["therapeutics"] -->|"inhibits"| neuroinflammation["neuroinflammation"]
Therapeutics["Therapeutics"] -->|"references"| SIRT6["SIRT6"]
Therapeutics["Therapeutics"] -->|"references"| AADC["AADC"]
Therapeutics["Therapeutics"] -->|"references"| CX3CR1["CX3CR1"]
Therapeutics["Therapeutics"] -->|"references"| BACE1["BACE1"]
Therapeutics["Therapeutics"] -->|"references"| APOE["APOE"]
Therapeutics["Therapeutics"] -->|"references"| VCP["VCP"]
Therapeutics["Therapeutics"] -->|"references"| GFAP["GFAP"]
Therapeutics["Therapeutics"] -->|"references"| NURR1["NURR1"]
Therapeutics["Therapeutics"] -->|"references"| BDNF["BDNF"]
Therapeutics["Therapeutics"] -->|"references"| NLRP3["NLRP3"]
Therapeutics["Therapeutics"] -->|"references"| TFEB["TFEB"]
Therapeutics["Therapeutics"] -->|"references"| PPARGC1A["PPARGC1A"]
style therapeutics fill:#4fc3f7,stroke:#333,color:#000
...Chelsea Therapeutics International
Company: Chelsea Therapeutics International, Ltd.
Status: Acquired by Lundbeck (2014)
Headquarters: Charlotte, North Carolina, USA (previously)
Founded: 2004
Acquired by: H. Lundbeck A/S (June 2014, ~$658M deal)
Overview
Mermaid diagram (expand to render)
Chelsea Therapeutics International was a biopharmaceutical company focused on the development and commercialization of products for the treatment of neurogenic orthostatic hypotension (nOH) and other disorders affecting the autonomic nervous system. The company's flagship product, [Northera (droxidopa) for neurogenic orthostatic hypotension](/therapeutics/droxidopa), received U.S. Food and Drug Administration (FDA) approval in 2014 for the treatment of symptomatic nOH, making it the first FDA-approved therapy for this indication["@droxidopa-fda"].
Chelsea Therapeutics was acquired by [H. Lundbeck A/S](/companies/lundbeck) in June 2014 for approximately $658 million, adding a critical product to Lundbeck's neuroscience portfolio while expanding into autonomic medicine["@droxidopa-chelsea"].
Droxidopa (Northera)
Mechanism of Action:
Droxidopa is a synthetic amino acid that serves as a prodrug of [norepinephrine](/entities/norepinephrine). Upon oral administration, droxidopa is converted to norepinephrine by the enzyme aromatic L-amino acid decarboxylase (AADC). This conversion occurs both in the periphery and in the CNS, allowing droxidopa to restore deficient norepinephrine levels in patients with autonomic failure[@northera-label].
Pharmacology:
- Acts as a prodrug: absorbed as droxidopa, converted to norepinephrine
- Restores sympathetic tone lost due to autonomic neuropathy
- Improves orthostatic tolerance through vasoconstriction and increased cardiac output
- Does not cross the blood-brain barrier significantly (peripheral conversion predominant)
Clinical Development:The development program for droxidopa included multiple Phase 3 clinical trials demonstrating:
Short-term efficacy: Statistically significant improvement in Orthostatic Hypotension Questionnaire (OHQ) composite score vs. placebo
Durability: Sustained benefit over 8-10 weeks of treatment
Symptom relief: Reduction in dizziness/lightheadedness, syncope, and fatigue
Motor symptom benefit: In PD patients, improvement in standing systolic blood pressure correlated with reduced motor symptomsClinical Trials:
| Trial | Phase | Population | Primary Endpoint | Result |
|-------|-------|------------|------------------|--------|
| NOH301 | Phase 3 | nOH (PD, PAF, diabetic neuropathy) | OHQ change from baseline | Positive |
| NOH302 | Phase 3 | nOH refractory to midodrine | OHQ, BP maintenance | Positive |
| NOH306 | Extension | Long-term safety | Safety/tolerability | Ongoing post-approval |
Orthostatic Hypotension in Parkinson's Disease
Patients with [Parkinson's disease](/diseases/parkinsons-disease) frequently develop neurogenic orthostatic hypotension due to:
- Cardiac sympathetic denervation: Loss of postganglionic sympathetic neurons
- Impaired baroreflex sensitivity: Reduced compensatory responses to positional changes
- Medication effects: Levodopa and dopamine agonists can worsen OH
- Alpha-synuclein pathology: Lewy body accumulation in autonomic neurons[@gibbons2019]
Droxidopa addresses the underlying norepinephrine deficiency, making it particularly valuable for PD patients with autonomic failure.
Product Portfolio
Northera (Droxidopa)
| Attribute | Details |
|-----------|---------|
| Brand Name | Northera |
| Generic Name | Droxidopa |
| Formulation | Oral capsules (100 mg, 200 mg, 300 mg) |
| Indication | Symptomatic neurogenic orthostatic hypotension |
| Approved Populations | Parkinson's disease, Multiple System Atrophy, Pure Autonomic Failure, Diabetic neuropathy |
| Dosing | 100-600 mg TID (three times daily) |
| FDA Approval Date | August 2014 |
| Schedule | Not scheduled (not a controlled substance) |
| Manufacturer | Lundbeck (post-acquisition) |
Efficacy in PD-Specific Studies:
Clinical trials specifically enriched for PD patients showed:
- Mean increase in systolic BP at 1 minute standing: ~15-20 mmHg vs. placebo
- Clinically meaningful improvement in dizziness (92% vs. 76% in placebo group)
- Reduction in fall risk associated with syncope
Safety Profile:
- Common: Headache, dizziness, nausea, hypertension (supine)
- Serious: Supine hypertension (requires bedtime dosing restriction), potential for cardiac arrhythmias
- Monitoring: Supine blood pressure monitoring required; avoid supine position for 2-3 hours after dosing
Lundbeck Acquisition
Deal Structure
In June 2014, Lundbeck acquired Chelsea Therapeutics for approximately $658 million, representing a 72% premium over Chelsea's closing stock price at the time.
Strategic Rationale for Lundbeck:
- Added FDA-approved product with strong differentiation in nOH
- Expanded into autonomic dysfunction — aligned with Lundbeck's CNS focus
- Established base in US specialty pharmaceutical market
- Droxidopa provided recurring revenue stream to fund pipeline investments
Post-Acquisition:
- Lundbeck commercialized Northera in the US market
- Expanded indication development (investigating PD-specific formulations)
- Integrated into Lundbeck's existing neurology sales infrastructure
Impact on PD Autonomic Dysfunction Treatment
Northera's approval represented a significant advance in the treatment of orthostatic hypotension in PD:
First-in-class mechanism: Droxidopa was the first norepinephrine prodrug approved specifically for nOH
Targeted approach: Addressed the underlying neurotransmitter deficiency rather than just treating symptoms
PD-specific benefit: Clinical trials demonstrated particular efficacy in PD patients with autonomic failure
Improved quality of life: Reduction in syncope, falls, and dizziness — leading causes of disability in PDThe availability of droxidopa also enabled combination therapy approaches:
- With midodrine: Sequential or concurrent use for refractory OH
- With fludrocortisone: For patients requiring additional volume expansion
- With physical countermeasures: Compression stockings, head-of-bed elevation
Related Pages
Disease and Mechanism Pages
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Autonomic Dysfunction in Parkinson's Disease](/mechanisms/parkinsons-autonomic-dysfunction)
- [Alpha-Synuclein Pathology](/mechanisms/alpha-synuclein-pathology)
- [Norepinephrine Signaling](/mechanisms/norepinephrine-signaling)
Treatment Pages
- [Droxidopa (Northera) Therapeutic Profile](/therapeutics/droxidopa)
- [Orthostatic Hypotension Treatments](/therapeutics/orthostatic-hypotension-treatments)
- [PD Non-Motor Symptom Treatments](/therapeutics/parkinsons-non-motor-symptoms)
Company Pages
- [H. Lundbeck A/S](/companies/lundbeck)
- [PD Autonomic Dysfunction Treatment Companies](/companies/pd-autonomic-dysfunction-treatments)
References
[FDA Approves Northera (droxidopa) for Neurogenic Orthostatic Hypotension (2014)](https://www.fda.gov/drugs/fda-approves-northera-droxidopa-neurogenic-orthostatic-hypotension)
[Chelsea Therapeutics Receives FDA Approval for Northera — BioSpace (2014)](https://www.biospace.com/chelsea-therapeutics-receives-fda-approval-for-northera-droxidopa)
[Gibbons CH, et al., Orthostatic hypotension in neurodegenerative disease, Clin Auton Res (2019)](https://pubmed.ncbi.nlm.nih.gov/30655302/)
[Northera (droxidopa) Full Prescribing Information (2022)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203202s015lbl.pdf)